Pasithea Therapeutics -CW26KTTAWPreferred / convertible
13F holders, Q2 2025 (June 30)5holders −1
1new positions
2sold out
1famous investor
$0.02avg. 13F price*
At the end of Q2 2025, 5 institutions reported holding Pasithea Therapeutics -CW26 (KTTAW) in their 13F filings, down 1 from Q1 2025. 1 opened new positions and 2 sold out. The largest holders were Kepos Capital LP ($7K), Armistice Capital, LLC ($1K) and Marex Group Ltd ($388). One famous investor held it Ken Griffin ( of Citadel Advisors's portfolio).
- Company
- Pasithea Therapeutics -CW26
- CUSIP
- 70261F111
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2025 → Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $335 |
| Exits | 2 | $2K |
All 13F filers, Q1 2025 → Q2 2025: 15,511 shares bought and 110,579 shares sold, net −95,068 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 5 holders
| Kepos Capital LP | — | No change | 334,600 | $7K |
| Armistice Capital, LLC | — | No change | 50,000 | $1K |
| Marex Group Ltd | — | No change | 25,000 | $388 |
| Citadel Advisors | — | New | 15,511 | $335 |
| Clear Street LLC | — | No change | 71 | $2 |
"% of holder's portfolio" is KTTAW's weight in each manager's 13F, not the share of Pasithea Therapeutics -CW26 the manager owns.